Xiaoguang “Margaret” Liu

Dr. Xiaoguang “Margaret” Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Redox Biology
Verified
Journal Article
Open access
KGKah Yong Goh
Kah Yong Goh
LHLi He
Li He
Jiajia SongJiajia Song
Jiajia Song
MJMiki Jinno
Miki Jinno
ARAaron J. Rogers
Aaron J. Rogers
Lufang ZhouLufang Zhou
Lufang Zhou
Increasing evidence indicates that mitochondrial-associated redox signaling contributes to the pathophysiology of heart failure (HF). The mitochondrial-targeted antioxidant, mitoquinone (MitoQ), is capable of modifying mitochondrial signaling and has shown beneficial effects on HF-dependent mitochondrial dysfunction. However, the potential therapeutic impact of MitoQ-based mitochondrial therapies for HF in response to pressure overload is reliant upon demonstration of improved cardiac contractile function and suppression of deleterious cardiac remodeling. Using a new (patho)physiologically relevant model of pressure overload-induced HF we tested the hypothesis that MitoQ is capable of ameliorating cardiac contractile dysfunction and suppressing fibrosis. To test this C57BL/6J mice were subjected to left ventricular (LV) pressure overload by ascending aortic constriction (AAC) followed by MitoQ treatment (2 µmol) for 7 consecutive days. Doppler echocardiography showed that AAC caused severe LV dysfunction and hypertrophic remodeling. MitoQ attenuated pressure overload-induced apoptosis, hypertrophic remodeling, fibrosis and LV dysfunction. Profibrogenic transforming growth factor-β1 (TGF-β1) and NADPH oxidase 4 (NOX4, a major modulator of fibrosis related redox signaling) expression increased markedly after AAC. MitoQ blunted TGF-β1 and NOX4 upregulation and the downstream ACC-dependent fibrotic gene expressions. In addition, MitoQ prevented Nrf2 downregulation and activation of TGF-β1-mediated profibrogenic signaling in cardiac fibroblasts (CF). Finally, MitoQ ameliorated the dysregulation of cardiac remodeling-associated long noncoding RNAs (lncRNAs) in AAC myocardium, phenylephrine-treated cardiomyocytes, and TGF-β1-treated CF. The present study demonstrates for the first time that MitoQ improves cardiac hypertrophic remodeling, fibrosis, LV dysfunction and dysregulation of lncRNAs in pressure overload hearts, by inhibiting the interplay between TGF-β1 and mitochondrial associated redox signaling.

9 October 2019 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
YSYingnan Si
Yingnan Si
SKSeulhee Kim
Seulhee Kim
EZEric Zhang
Eric Zhang
YTYawen Tang
Yawen Tang
RJRenata Jaskula‐Sztul
Renata Jaskula‐Sztul
MLMargaret Liu
Margaret Liu

26 August 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZhuoxin “Zora” Zhou
Zhuoxin “Zora” Zhou
YSYingnan Si
Yingnan Si
JZJiashuai Zhang
Jiashuai Zhang
KCKai Chen
Kai Chen
AGAshley George
Ashley George
MLMargaret Liu
Margaret Liu
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies and cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC. In this study, we aimed to develop an antibody–drug conjugate with dual payloads (DualADC) as a chemoimmunotherapy for TNBC. The overexpression of an immune checkpoint transmembrane CD276 (also known as B7-H3) was associated with angiogenesis, metastasis, and immune tolerance in more than 60% of patients with TNBC. Development of a mAb capable of targeting the extracellular domain of surface CD276 enabled delivery of payloads to tumors, and a platform was established for concurrent conjugation of a traditional cytotoxic payload and an immunoregulating Toll-like receptor 7/8 agonist to the CD276 mAb. The DualADC effectively killed multiple TNBC subtypes, significantly enhanced immune functions in the tumor microenvironment, and reduced tumor burden by up to 90% to 100% in animal studies. Single-cell RNA sequencing, multiplex cytokine analysis, and histology elucidated the impact of treatment on tumor cells and the immune landscape. This study suggests that the developed DualADC could represent a promising targeted chemoimmunotherapy for TNBC. Significance: An anti-CD276 monoclonal antibody conjugated with both a cytotoxic drug and an immune boosting reagent effectively targets triple-negative breast cancer by inducing tumor cell death and stimulating immune cell infiltration.

20 July 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
YSYingnan Si
Yingnan Si
SKSeulhee Kim
Seulhee Kim
JOJianfa Ou
Jianfa Ou
YLYun Lu
Yun Lu
PEPatrick Ernst
Patrick Ernst
MLMargaret Liu
Margaret Liu

28 January 2022 in Frontiers in Chemical Engineering
Verified
Journal Article
Open access
JGJia-Shiung Guan
Jia-Shiung Guan
KCKai Chen
Kai Chen
YSYingnan Si
Yingnan Si
TKTaehyun Kim
Taehyun Kim
ZZZhuoxin Zhou
Zhuoxin Zhou
MLMargaret Liu
Margaret Liu
Adeno-associated viruses (AAVs) have been well characterized and used to deliver therapeutic genes for diseases treatment in clinics and basic research. This study used the triple transient transfection of AAV-DJ/8 as a model expression system to develop and optimize the laboratory production of AAV for research and pre-clinical applications. Specifically, various production parameters, including host cell, transfection reagent, cell density, ratio of plasmid DNA and cells, gene size, and production mode, were tested to determine the optimal process. Our results showed that the adherent production using HEK 293AAV with calcium transfection generated the highest volumetric productivity of 7.86 × 109 gc/ml. The optimal suspensive production using HEK 293F had best AAV productivity of 5.78 × 109 gc/ml in serum-free medium under transfection conditions of transfection density of 0.4 × 106 cells/ml, plasmid DNA:cells ratio of 1.6 µg:106 cells and synthesized cationic liposomes as transfection reagent. The similar AAV productivity was confirmed at scales of 30–450 ml in shaker and/or spinner flasks. The in vitro transfection and in vivo infection efficiency of the harvested AAV-DJ/8 carrying luciferase reporter gene was confirmed using cell line and xenograft mouse model, respectively. The minimal or low purification recovery rate of AAV-DJ/8 in ion-exchange chromatography column and affinity column was observed in this study. In summary, we developed and optimized a scalable suspensive production of AAV to support the large-scale preclinical animal studies in research laboratories.

1 October 2014 in Cancer Letters
Verified
Journal Article
Closed access
Lufang ZhouLufang Zhou
Lufang Zhou
NXNingning Xu
Ningning Xu
YSYan Sun
Yan Sun
MLMargaret Liu
Margaret Liu